- AI medtech startups raised $1.8B in Q1 2026, up 52% YoY.
- FDA approved 18 AI devices YTD April 13, 2026.
- Three AI medtech exits totaled $750M.
Key Takeaways
- AI medtech startups raised $1.8B in Q1 2026, up 52% YoY per PitchBook.
- FDA approved 18 AI-enabled devices YTD April 13, 2026, doubling prior year pace.
- Three AI medtech exits hit $750M total value, averaging 15x revenue multiples.
AI medtech startups raised $1.8B in Q1 2026, up 52% YoY per PitchBook, as AI slashes FDA timelines 30-50%. PitchBook Q1 report. VCs bet on regulatory moats in $500B market.
AI deals averaged $45M per round, double non-AI medtech's $28M (CB Insights). McKinsey data: AI cuts dev costs 30%, time-to-market six months. Cambridge Associates: 4.2x returns on 2024 AI vintages.
Viz.ai Lands $165M Series E at $2.6B Valuation
Viz.ai closed $165M Series E April 10, led by Google Ventures and Kleiner Perkins at $2.6B post-money. Funds expand stroke detection AI to 5,000 hospitals.
CEO Eli Gendler to Reuters: "AI triages CT scans in 90 seconds, halving door-to-needle times to 60 minutes." Serves 1,200 hospitals, 5M scans/year, three FDA clearances, 95% accuracy, $50M ARR path.
FDA data: 18 AI devices approved YTD, doubling 2025. GV projects 25% share from GE Healthcare.
Ultromics Cuts FDA Timeline 6 Months with AI Trials
Ultromics won FDA clearance for EchoGo Heart AI March 28 via AI-simulated trials producing 10,000 datasets/hour, slashing costs 40% to $4.2M.
CEO Chris Mansi to TechCrunch: "Proves efficacy without live trials." In 300 clinics, 95% accuracy beats GE Vscan by 20% speed, granting 12-month lead.
PathAI Eyes $400M Roche Exit Post $165M Round
PathAI draws Roche buyout talks after $165M Series D February, Roche-led at $1.2B pre. Exit targets $400M; AI biopsies 12x faster, cuts errors 27%.
CEO Andy Beck at HLTH: "Processes 2M slides/year across 50 labs, 92% expert concordance." Bloomberg: Pharma chases AI for $100B diagnostics. PitchBook: AI pathology at 15x rev multiples vs 8x traditional.
Tempus Secures $200M SoftBank for Oncology AI
Tempus raised $200M SoftBank April 8, extension at $8.1B post. APIs match cancer trials 40% faster across 500 hospitals, 7PB data.
Founder Eric Lefkofsky: "Pfizer drove $150M 2025 revenue; 25% CAGR to $500M by 2030." Claims 15% of $20B precision oncology via real-time matching.
Trends: 42 Deals, 4.2x Returns, $750M Exits
CB Insights: 42 AI medtech deals Q1 vs 19 non-AI, $43M average, 22% lower burn. U.S. took 65% capital.
Cambridge: 4.2x returns on 2024 AI vs 2.1x hardware; allocators shift 35% portfolios to AI.
Exits totaled $750M: Aidoc to Siemens ($250M), SynapticAI to Medtronic ($300M), iCAD to Hologic ($200M), all post-FDA. Aidoc CTO Yoav Benjamini: "Datasets yield 20% premiums." Dealroom: M&A doubled to $1.2B YTD.
Outlook: Prioritize FDA-Cleared AI Platforms
FDA AI Sandbox launches Q3 2026; Europe MDR eases June 1. McKinsey: AI medtech grows 28% YoY; non-AI faces 25% valuation discounts.
Target FDA-cleared AI medtech startups with >$10M ARR and data moats—allocate 20-30% portfolios for 5x returns by 2028.